Present research situation and prospect of rheumatoid arthritis and depression_West China Medical Journal

Authors：

REN Yan ¹ ,  YIN Geng ²

1. Department of General Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Special Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

YIN Geng, Email: yingeng1975@163.com

Keywords：

Rheumatoid arthritis; Depression; Antitumor necrosis factor-α

DOI：

10.7507/1002-0179.201808050

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The incidence of depression in patients with rheumatoid arthritis is higher. The concomitant depression will increase medical expense, reduce drug efficacy, lower its compliance, increase the incidence of complication, and affect the cure of rheumatoid arthritis. The influence of depression to rheumatoid arthritis is usually ignored in clinical work. In recent years, the pertinence between depression and immune disease in pathogenesis is found in research: depression will increase the risk of immune diseases in activate inflammation as well as extend and promote the release of inflammatory factors. This article reviews research progress of correlation between depression and rheumatoid arthritis.

Citation： REN Yan, YIN Geng. Present research situation and prospect of rheumatoid arthritis and depression. West China Medical Journal, 2018, 33(12): 1554-1557. doi: 10.7507/1002-0179.201808050 Copy

1.	Joyce AT, Smith P, Khandker R, et al. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol, 2009, 36(4): 743-752.
2.	Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum, 2014, 44(2): 123-130.
3.	Lok EY, Mok CC, Cheng CW, et al. Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. Psychosomatics, 2010, 51(4): 338-338.e8.
4.	Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology, 2013, 52(12): 2136-2148.
5.	杨春军, 王君颖, 孙春艳, 等. 我国类风湿关节炎患者抑郁患病率的 Meta 分析. 中华风湿病学杂志, 2015, 19(10): 662-668.
6.	Andersson NW, Gustafsson LN, Okkels N, et al. Depression and the risk of autoimmune disease: a nationally representative, prospective longitudinal study. Psychol Med, 2015, 45(16): 3559-3569.
7.	Tsai TY, Lu MC, Livneh H, et al. Does depression increase the risk of stroke in patients with rheumatoid arthritis? A population-based cohort study. BMJ Open, 2017, 7(4): e014233.
8.	Matcham F, Ali S, Irving K, et al. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study. BMC Musculoskelet Disord, 2016, 17: 155.
9.	Kekow J, Moots R, Khandker R, et al. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology, 2011, 50(2): 401-409.
10.	Xia Y, Yin R, Fu T, et al. Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Prefer Adherence, 2016, 10: 735-742.
11.	van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol, 1994, 8(4): 337-351.
12.	Ofman JJ, Badamgarav E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med, 2004, 117(3): 182-192.
13.	Matcham F, Davies R, Hotopf M, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology Biologics Register. Rheumatology, 2018, 57(5): 835-843.
14.	Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull, 2014, 140(3): 774-815.
15.	Lopresti AL, Maker GL, Hood SD, et al. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 48: 102-111.
16.	Camara ML, Corrigan F, Jaehne EJ, et al. Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology, 2015, 40(2): 502-512.
17.	Ortega A, Jadeja V, Zhou H. Postnatal development of lipopolysaccharide-induced inflammatory response in the brain. Inflamm Res, 2011, 60(2): 175-185.
18.	Chen J, Song Y, Yang J, et al. The contribution of TNF-alpha in the amygdala to anxiety in mice with persistent inflammatory pain. Neurosci Lett, 2013, 541(29): 275-280.
19.	Camara ML, Corrigan F, Jaehne EJ, et al. TNF-alpha and its receptors modulate complex behaviours and neurotrophins in transgenic mice. Psychoneuroendocrinology, 2013, 38(12): 3102-3114.
20.	Abbott R, Whear R, Nikolaou V, et al. Tumour necrosis factor-alpha inhibitor therapy in chronic physical illness: a systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res, 2015, 79(3): 175-184.
21.	Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest, 2008, 118(2): 413-420.
22.	Slavich GM, Cole SW. The emerging field of human social genomics. Clin Psychol Sci, 2013, 1(3): 331-348.
23.	Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol, 2005, 5(3): 243-251.
24.	Anisman H, Matheson K. Stress, depression, and anhedonia: caveats concerning animal models. Neurosci Biobehav Rev, 2005, 29(4-5): 525-546.
25.	Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol, 2011, 11(9): 625-632.
26.	Jarcho MR, Slavich GM, Tylova-Stein HA, et al. Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol Psychol, 2013, 93(1): 150-158.
27.	O’donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun, 2010, 24(7): 1074-1077.

1. Joyce AT, Smith P, Khandker R, et al. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol, 2009, 36(4): 743-752.
2. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum, 2014, 44(2): 123-130.
3. Lok EY, Mok CC, Cheng CW, et al. Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. Psychosomatics, 2010, 51(4): 338-338.e8.
4. Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology, 2013, 52(12): 2136-2148.
5. 杨春军, 王君颖, 孙春艳, 等. 我国类风湿关节炎患者抑郁患病率的 Meta 分析. 中华风湿病学杂志, 2015, 19(10): 662-668.
6. Andersson NW, Gustafsson LN, Okkels N, et al. Depression and the risk of autoimmune disease: a nationally representative, prospective longitudinal study. Psychol Med, 2015, 45(16): 3559-3569.
7. Tsai TY, Lu MC, Livneh H, et al. Does depression increase the risk of stroke in patients with rheumatoid arthritis? A population-based cohort study. BMJ Open, 2017, 7(4): e014233.
8. Matcham F, Ali S, Irving K, et al. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study. BMC Musculoskelet Disord, 2016, 17: 155.
9. Kekow J, Moots R, Khandker R, et al. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology, 2011, 50(2): 401-409.
10. Xia Y, Yin R, Fu T, et al. Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Prefer Adherence, 2016, 10: 735-742.
11. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol, 1994, 8(4): 337-351.
12. Ofman JJ, Badamgarav E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med, 2004, 117(3): 182-192.
13. Matcham F, Davies R, Hotopf M, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology Biologics Register. Rheumatology, 2018, 57(5): 835-843.
14. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull, 2014, 140(3): 774-815.
15. Lopresti AL, Maker GL, Hood SD, et al. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 48: 102-111.
16. Camara ML, Corrigan F, Jaehne EJ, et al. Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology, 2015, 40(2): 502-512.
17. Ortega A, Jadeja V, Zhou H. Postnatal development of lipopolysaccharide-induced inflammatory response in the brain. Inflamm Res, 2011, 60(2): 175-185.
18. Chen J, Song Y, Yang J, et al. The contribution of TNF-alpha in the amygdala to anxiety in mice with persistent inflammatory pain. Neurosci Lett, 2013, 541(29): 275-280.
19. Camara ML, Corrigan F, Jaehne EJ, et al. TNF-alpha and its receptors modulate complex behaviours and neurotrophins in transgenic mice. Psychoneuroendocrinology, 2013, 38(12): 3102-3114.
20. Abbott R, Whear R, Nikolaou V, et al. Tumour necrosis factor-alpha inhibitor therapy in chronic physical illness: a systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res, 2015, 79(3): 175-184.
21. Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest, 2008, 118(2): 413-420.
22. Slavich GM, Cole SW. The emerging field of human social genomics. Clin Psychol Sci, 2013, 1(3): 331-348.
23. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol, 2005, 5(3): 243-251.
24. Anisman H, Matheson K. Stress, depression, and anhedonia: caveats concerning animal models. Neurosci Biobehav Rev, 2005, 29(4-5): 525-546.
25. Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol, 2011, 11(9): 625-632.
26. Jarcho MR, Slavich GM, Tylova-Stein HA, et al. Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol Psychol, 2013, 93(1): 150-158.
27. O’donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun, 2010, 24(7): 1074-1077.

West China Medical Journal

Present research situation and prospect of rheumatoid arthritis and depression

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content